Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction.
J Stroke Cerebrovasc Dis 2013; 22(5):668-74JS

Abstract

BACKGROUND

The free radical scavenger edaravone has been reported useful for improvement in activities of daily living and for prevention of recurrent stroke in the edaravone versus sodium ozagrel in acute noncardioembolic ischemic stroke (EDO) trial. The aim of this report was to evaluate the cost-effectiveness of edaravone compared to the intravenous antiplatelet drug ozagrel sodium (ozagrel) for noncardioembolic stroke (non-CES) based on the EDO trial data.

METHODS

A cost-effectiveness analysis was performed using the Markov model, which also incorporated the long-term course after the acute stage of non-CES. From the perspective of a health care payer, direct medical costs and nursing care costs were taken into account in the cost analysis. The quality-adjusted life year (QALY) served as an indicator of effectiveness. Simulation at 5 and 10 years after the onset of non-CES was carried out. The study involved 68-year-old patients with non-CES, selected against the EDO trial subject selection criteria. A 14-day treatment with edaravone 60 mg/day or ozagrel 160 mg/day was assumed as acute treatment for non-CES.

RESULTS

The use of edaravone was associated with a reduction in total costs (0.51 million yen [$6,374] at 5 years and 0.64 million yen [$8,039]) at 10 years after the onset of non-CES) and improvement in QALYs (0.23 at 5 years and 0.38 at 10 years). Compared to ozagrel therapy, edaravone therapy was a cost-saving strategy for treating non-CES.

CONCLUSIONS

Compared to ozagrel therapy, edaravone therapy for non-CES is not only useful from a clinical viewpoint, but also valuable from a socioeconomic perspective.

Authors+Show Affiliations

Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tachikawa, Tokyo, Japan. yshinoha@tachikawa-hosp.gr.jpNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

22622391

Citation

Shinohara, Yukito, and Sachie Inoue. "Cost-effectiveness Analysis of the Neuroprotective Agent Edaravone for Noncardioembolic Cerebral Infarction." Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, vol. 22, no. 5, 2013, pp. 668-74.
Shinohara Y, Inoue S. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. J Stroke Cerebrovasc Dis. 2013;22(5):668-74.
Shinohara, Y., & Inoue, S. (2013). Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, 22(5), pp. 668-74. doi:10.1016/j.jstrokecerebrovasdis.2012.04.002.
Shinohara Y, Inoue S. Cost-effectiveness Analysis of the Neuroprotective Agent Edaravone for Noncardioembolic Cerebral Infarction. J Stroke Cerebrovasc Dis. 2013;22(5):668-74. PubMed PMID: 22622391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. AU - Shinohara,Yukito, AU - Inoue,Sachie, Y1 - 2012/05/22/ PY - 2012/02/14/received PY - 2012/04/02/revised PY - 2012/04/03/accepted PY - 2012/5/25/entrez PY - 2012/5/25/pubmed PY - 2014/2/8/medline SP - 668 EP - 74 JF - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association JO - J Stroke Cerebrovasc Dis VL - 22 IS - 5 N2 - BACKGROUND: The free radical scavenger edaravone has been reported useful for improvement in activities of daily living and for prevention of recurrent stroke in the edaravone versus sodium ozagrel in acute noncardioembolic ischemic stroke (EDO) trial. The aim of this report was to evaluate the cost-effectiveness of edaravone compared to the intravenous antiplatelet drug ozagrel sodium (ozagrel) for noncardioembolic stroke (non-CES) based on the EDO trial data. METHODS: A cost-effectiveness analysis was performed using the Markov model, which also incorporated the long-term course after the acute stage of non-CES. From the perspective of a health care payer, direct medical costs and nursing care costs were taken into account in the cost analysis. The quality-adjusted life year (QALY) served as an indicator of effectiveness. Simulation at 5 and 10 years after the onset of non-CES was carried out. The study involved 68-year-old patients with non-CES, selected against the EDO trial subject selection criteria. A 14-day treatment with edaravone 60 mg/day or ozagrel 160 mg/day was assumed as acute treatment for non-CES. RESULTS: The use of edaravone was associated with a reduction in total costs (0.51 million yen [$6,374] at 5 years and 0.64 million yen [$8,039]) at 10 years after the onset of non-CES) and improvement in QALYs (0.23 at 5 years and 0.38 at 10 years). Compared to ozagrel therapy, edaravone therapy was a cost-saving strategy for treating non-CES. CONCLUSIONS: Compared to ozagrel therapy, edaravone therapy for non-CES is not only useful from a clinical viewpoint, but also valuable from a socioeconomic perspective. SN - 1532-8511 UR - https://www.unboundmedicine.com/medline/citation/22622391/Cost_effectiveness_analysis_of_the_neuroprotective_agent_edaravone_for_noncardioembolic_cerebral_infarction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1052-3057(12)00099-7 DB - PRIME DP - Unbound Medicine ER -